Parkinson's Treatment Kit Using Segmented AADC and Levodopa Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease and other neurodegenerative disorders with motor complications fail to achieve continuous dopaminergic stimulation, leading to motor fluctuations and dyskinesias due to discontinuous levodopa administration.
Innovation Solution
A kit and method combining an oral Modified Release formulation of an AADC-inhibitor (benserazide or carbidopa) with a subcutaneous infusion or oral Modified Release formulation of levodopa, along with optional COMT-inhibition, to achieve continuous inhibition of peripheral levodopa metabolism and stable levodopa plasma levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral levodopa treatment is administered in fixed combination with AADC-inhibitor, then the treatment is simple and widely applicable, but the AADC-inhibitor dose cannot be optimized to attain stronger inhibition of peripheral DOPA decarboxylation
Solution Approach 1:
The patent separates the levodopa and AADC-inhibitor into different dosage forms: levodopa is provided as a subcutaneous infusion (continuous delivery) while the AADC-inhibitor is provided as an oral modified-release formulation. This segmentation allows independent optimization of each component's dosage and release characteristics, enabling stronger and more sustained peripheral inhibition without compromising treatment simplicity.
Solution Approach 2:
The patent employs modified-release formulations of the AADC-inhibitor that provide periodic dosing (e.g., twice daily) with sustained release over extended periods. This periodic administration pattern maintains stable plasma concentrations of the inhibitor, ensuring continuous peripheral blockade of levodopa metabolism while simplifying the patient's dosing routine compared to multiple daily administrations.
2Adaptability or versatility
If immediate release formulations of levodopa and AADC-inhibitor are administered multiple times per day, then the treatment can be adjusted to individual needs, but the peak-trough amplitude in plasma levels is high causing motor fluctuations
Solution Approach 1:
The patent implements continuous subcutaneous infusion of levodopa, which provides a constant, controlled delivery rate directly into the subcutaneous tissue. This continuous administration eliminates the peak-trough fluctuations associated with oral immediate-release formulations, maintaining stable plasma levodopa concentrations and preventing motor fluctuations while still allowing dose adjustment by modifying the infusion rate.
Solution Approach 2:
The patent uses modified-release formulations of the AADC-inhibitor that are designed to release the drug over extended periods (e.g., 12-24 hours). This preliminary formulation design ensures that the inhibitor is released gradually, maintaining stable plasma levels and continuous peripheral blockade before the next dose is administered, thereby preventing fluctuations in levodopa metabolism inhibition.
3Reliability
If high doses of levodopa are administered to achieve sufficient plasma levels, then the therapeutic effect is improved, but the risk of peripheral side effects increases
Solution Approach 1:
The patent introduces a strongly inhibiting AADC-inhibitor as an intermediary that blocks peripheral levodopa metabolism. By administering the inhibitor orally in modified-release formulation, the patent achieves near-complete peripheral blockade, allowing the use of low-dose subcutaneous levodopa infusion (3-6 mg/h) to achieve therapeutic plasma levels without the peripheral side effects associated with high oral levodopa doses. The inhibitor acts as a mediator that protects against peripheral conversion of levodopa to dopamine.
4Duration of action of moving object
If the half-life of AADC-inhibitors is extended, then the dosing frequency can be reduced, but the current short half-life requires frequent administrations
Solution Approach 1:
The patent changes the release parameters of the AADC-inhibitor by using modified-release formulations that extend the release duration to 12-24 hours. This parameter change in the formulation's release kinetics effectively extends the functional duration of action of the inhibitor, allowing dosing only twice daily or even once daily, thereby simplifying the treatment regimen while maintaining stable plasma concentrations and continuous peripheral inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for continuous dopaminergic stimulation, reducing the need for frequent drug administrations, minimizing motor fluctuations, and achieving high and stable levodopa plasma levels sufficient for treating advanced Parkinson's disease stages.
Implementation Method 1
an almost complete inhibition of the peripheral levodopa metabolism
Implementation Method 2
peripheral levodopa metabolism to achieve Continuous Dopaminergic Stimulation
Data Source
AI summary
The invention relates to the treatment of neurodegenerative diseases such as Parkinson patients with motor complications in need of Continuous Dopaminergic Stimulation. According to the invention a kit of pharmaceutical preparations is provided comprising levodopa and an AADC-inhibitor. Levodopa is applied via continuous subcutaneous infusion or by an oral modified release formulation and Continuous Dopaminergic Stimulation is achieved by almost complete inhibition of the peripheral levodopa metabolism. To reach far-going blockage of levodopa metabolism, an AADC-inhibitor (e.g., benserazide, carbidopa) is given orally in a much higher than normal dose and, as an indispensable prerequisite, the AADC-inhibitor has to be applied evenly distributed over the day. e.g., via a Modified Release formulation. In order to prevent levodopa conjugation over the COMT pathway, an oral COMT-inhibitor (e.g., opicapone) is also added. In addition, a drug-drug-interaction between the AADC-inhibitor and opicapone further increasing the activity of the former is likely to occur. The resulting effective inhibition of peripheral levodopa metabolism allows a marked reduction of the necessary (equivalent) levodopa (or prodrug) doses to 300-600 mg/day, which is, however, sufficient to reach high levodopa plasma levels of 1500 to 3000 ng/ml. The low daily levodopa dose is infused subcutaneously via minipump and is well-tolerated at the infusion site. Alternatively, the low daily levodopa dose is provided as an oral modified release formulation. The high steady-state levodopa plasma levels reached, allow effective Continuous Dopaminergic Stimulation-therapy for Parkinson's disease patients of any degree of severity. As additional benefit, the largely complete AADC-inhibition prevents the peripheral generation of dopamine and the cumbersome dopaminergic adverse effects (e.g., nausea, cardiovascular and gastro-intestinal adverse effects) are prevented.